Le Lézard
Classified in: Health, Sports and recreation
Subjects: AVO, MAT

DEA Rescheduling of Cannabis A Big Win for Patients


Cannabis Freedom Party Lauds the Decision to Move Cannabis to Schedule 3

WASHINGTON, April 30, 2024 /PRNewswire/ -- The Cannabis Freedom Party (CFP) is very pleased to learn of the news from the Associated Press that the U.S. Drug Enforcement Administration will move to reclassify cannabis as a Schedule 3 drug. The CFP sees this reclassification as a major win for the industry and patients.

"Moving cannabis from Schedule 1 to a Schedule 3 drug on the Controlled Substances List is just the first winning drive in what's going to be a long hard-fought game to bring about an end to the War on Drugs. While some may say that descheduling is truly what's needed, today's decision put necessary points on the board for medical cannabis patients across this country," said Ricky Williams, Co-Founder of CFP.

According to the DEA, Schedule III drugs, substances, or chemicals are defined as drugs with a moderate to low potential for physical and psychological dependence. Schedule III drugs abuse potential is less than Schedule I and Schedule II drugs but more than Schedule IV. Some examples of Schedule III drugs are: products containing less than 90 milligrams of codeine per dosage unit (Tylenol with codeine), ketamine, anabolic steroids, testosterone.

"We have long believed in the therapeutic potential of cannabis, and we've witnessed firsthand its ability to alleviate a wide range of conditions including the repercussions of years of injuries from the NFL. The rescheduling of cannabis to Schedule 3, this will now open the door for countless other patients who need access to this life saving medicine," said Jim McMahon, Co-Founder of CFP.

"This will also bring about the end to 280-E, the crushing tax code which has burdened so many legal cannabis businesses for the past 10 years. This will help bring about more investment into the space and allow legal businesses to finally benefit from federal tax deductions. Our hope now is that the federal government will move swiftly to get this reclassification implemented and let cannabis have the necessary first touchdown it so desperately needs," said Kyle Turley, Co-Founder of CFP.

About Cannabis Freedom Party
The Cannabis Freedom Party (CFP) mobilizes communities for voter outreach, advocates tirelessly for cannabis normalization, and upholds the principles of personal choice. At CFP, our passion fuels a movement for change, inviting everyone to join us in breaking down stigmas and championing the rights to wellness and freedom. Stand with us, contribute to our cause, and together, let's create a future where the value of cannabis and the power of choice are recognized and celebrated.

Media Contact:
Gretchen Gailey
[email protected]
202.489.3821

SOURCE Cannabis Freedom Party


These press releases may also interest you

at 01:39
Hansa Biopharma, "Hansa" , will publish its interim report for January-June 2024 on July 18, 2024. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST/8:00 AM EST. The event will be hosted by Søren...

at 01:05
Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today announces a change to its Executive Leadership Team...

at 00:15
In the news release, AbbVie, Inc.'s Zymaxid tm Implicated in Product Liability Lawsuit Due to Risk of Serious Injury and Death, issued 02-Jul-2024 by Wormington & Bollinger over PRWeb, the source of the release should be "Wormington & Bollinger"...

at 00:00
Author David W. Treaster shares a Christian-based plan that can supplement a cancer patient's medical treatment plan in God Power Cancer Healing Plan: Spiritual Component ($15.99, paperback, 9781662899942; $7.99, e-book, 9781662899959). As long as...

2 jui 2024
In a groundbreaking medical feat, LiverIndia's Dr Karthik Mathivanan, a renowned Liver Transplant surgeon in Chennai with over 15 years of experience in multi-organ transplant surgery, has successfully utilised the emerging field of transplant...

2 jui 2024
Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 225Ac-FL-020, the company's lead radiopharmaceutical,...



News published on and distributed by: